Pharma & Healthcare
Global Pre-Exposure Prophylaxis (PrEP) Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 21, 25
- ID: 553933
- Pages: 154
- Figures: 154
- Views: 7
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Pre-Exposure Prophylaxis (PrEP) market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Gilead Sciences
ViiV Healthcare
Teva
Amneal Pharmaceuticals
Aurobindo Pharma
Mylan
Zydus
Qilu Pharmaceutical
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Segment by Type
Oral PrEP
Injectable PrEP
Segment by Application
Hospital and Clinic
Pharmacy
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Pre-Exposure Prophylaxis (PrEP) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Pre-Exposure Prophylaxis (PrEP) market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Gilead Sciences
ViiV Healthcare
Teva
Amneal Pharmaceuticals
Aurobindo Pharma
Mylan
Zydus
Qilu Pharmaceutical
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Segment by Type
Oral PrEP
Injectable PrEP
Segment by Application
Hospital and Clinic
Pharmacy
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Pre-Exposure Prophylaxis (PrEP) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Pre-Exposure Prophylaxis (PrEP): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pre-Exposure Prophylaxis (PrEP) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Oral PrEP
1.2.3 Injectable PrEP
1.3 Market Segmentation by Application
1.3.1 Global Pre-Exposure Prophylaxis (PrEP) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Pre-Exposure Prophylaxis (PrEP) Revenue Estimates and Forecasts 2020-2031
2.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Estimates and Forecasts 2020-2031
2.4 Global Pre-Exposure Prophylaxis (PrEP) Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Pre-Exposure Prophylaxis (PrEP) Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Oral PrEP Market Size by Manufacturers
3.5.2 Injectable PrEP Market Size by Manufacturers
3.6 Global Pre-Exposure Prophylaxis (PrEP) Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Pre-Exposure Prophylaxis (PrEP) Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Type (2020-2031)
6.4 North America Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Pre-Exposure Prophylaxis (PrEP) Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Type (2020-2031)
7.4 Europe Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Pre-Exposure Prophylaxis (PrEP) Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Type (2020-2031)
9.4 Central and South America Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Pre-Exposure Prophylaxis (PrEP) Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Gilead Sciences
11.1.1 Gilead Sciences Corporation Information
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.1.4 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Sales by Product in 2024
11.1.6 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Sales by Application in 2024
11.1.7 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Sales by Geographic Area in 2024
11.1.8 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
11.1.9 Gilead Sciences Recent Developments
11.2 ViiV Healthcare
11.2.1 ViiV Healthcare Corporation Information
11.2.2 ViiV Healthcare Business Overview
11.2.3 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.2.4 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Sales by Product in 2024
11.2.6 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Sales by Application in 2024
11.2.7 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Sales by Geographic Area in 2024
11.2.8 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
11.2.9 ViiV Healthcare Recent Developments
11.3 Teva
11.3.1 Teva Corporation Information
11.3.2 Teva Business Overview
11.3.3 Teva Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.3.4 Teva Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Teva Pre-Exposure Prophylaxis (PrEP) Sales by Product in 2024
11.3.6 Teva Pre-Exposure Prophylaxis (PrEP) Sales by Application in 2024
11.3.7 Teva Pre-Exposure Prophylaxis (PrEP) Sales by Geographic Area in 2024
11.3.8 Teva Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
11.3.9 Teva Recent Developments
11.4 Amneal Pharmaceuticals
11.4.1 Amneal Pharmaceuticals Corporation Information
11.4.2 Amneal Pharmaceuticals Business Overview
11.4.3 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.4.4 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Sales by Product in 2024
11.4.6 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Sales by Application in 2024
11.4.7 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Sales by Geographic Area in 2024
11.4.8 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
11.4.9 Amneal Pharmaceuticals Recent Developments
11.5 Aurobindo Pharma
11.5.1 Aurobindo Pharma Corporation Information
11.5.2 Aurobindo Pharma Business Overview
11.5.3 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.5.4 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Sales by Product in 2024
11.5.6 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Sales by Application in 2024
11.5.7 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Sales by Geographic Area in 2024
11.5.8 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
11.5.9 Aurobindo Pharma Recent Developments
11.6 Mylan
11.6.1 Mylan Corporation Information
11.6.2 Mylan Business Overview
11.6.3 Mylan Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.6.4 Mylan Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Mylan Recent Developments
11.7 Zydus
11.7.1 Zydus Corporation Information
11.7.2 Zydus Business Overview
11.7.3 Zydus Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.7.4 Zydus Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Zydus Recent Developments
11.8 Qilu Pharmaceutical
11.8.1 Qilu Pharmaceutical Corporation Information
11.8.2 Qilu Pharmaceutical Business Overview
11.8.3 Qilu Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.8.4 Qilu Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Qilu Pharmaceutical Recent Developments
11.9 Anhui Baker Biopharmaceutical
11.9.1 Anhui Baker Biopharmaceutical Corporation Information
11.9.2 Anhui Baker Biopharmaceutical Business Overview
11.9.3 Anhui Baker Biopharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.9.4 Anhui Baker Biopharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Anhui Baker Biopharmaceutical Recent Developments
11.10 Chengdu Brilliant Pharmaceutical
11.10.1 Chengdu Brilliant Pharmaceutical Corporation Information
11.10.2 Chengdu Brilliant Pharmaceutical Business Overview
11.10.3 Chengdu Brilliant Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.10.4 Chengdu Brilliant Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Chengdu Brilliant Pharmaceutical Recent Developments
11.11 North China Pharmaceutical
11.11.1 North China Pharmaceutical Corporation Information
11.11.2 North China Pharmaceutical Business Overview
11.11.3 North China Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.11.4 North China Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 North China Pharmaceutical Recent Developments
11.12 Chia Tai Tianqing Pharmaceutical
11.12.1 Chia Tai Tianqing Pharmaceutical Corporation Information
11.12.2 Chia Tai Tianqing Pharmaceutical Business Overview
11.12.3 Chia Tai Tianqing Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.12.4 Chia Tai Tianqing Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Pre-Exposure Prophylaxis (PrEP) Industry Chain
12.2 Pre-Exposure Prophylaxis (PrEP) Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Pre-Exposure Prophylaxis (PrEP) Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Pre-Exposure Prophylaxis (PrEP) Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Pre-Exposure Prophylaxis (PrEP) Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Pre-Exposure Prophylaxis (PrEP) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Pre-Exposure Prophylaxis (PrEP): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pre-Exposure Prophylaxis (PrEP) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Oral PrEP
1.2.3 Injectable PrEP
1.3 Market Segmentation by Application
1.3.1 Global Pre-Exposure Prophylaxis (PrEP) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Pre-Exposure Prophylaxis (PrEP) Revenue Estimates and Forecasts 2020-2031
2.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Estimates and Forecasts 2020-2031
2.4 Global Pre-Exposure Prophylaxis (PrEP) Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Pre-Exposure Prophylaxis (PrEP) Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Oral PrEP Market Size by Manufacturers
3.5.2 Injectable PrEP Market Size by Manufacturers
3.6 Global Pre-Exposure Prophylaxis (PrEP) Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Pre-Exposure Prophylaxis (PrEP) Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Type (2020-2031)
6.4 North America Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Pre-Exposure Prophylaxis (PrEP) Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Type (2020-2031)
7.4 Europe Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Pre-Exposure Prophylaxis (PrEP) Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Type (2020-2031)
9.4 Central and South America Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Pre-Exposure Prophylaxis (PrEP) Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Gilead Sciences
11.1.1 Gilead Sciences Corporation Information
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.1.4 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Sales by Product in 2024
11.1.6 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Sales by Application in 2024
11.1.7 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Sales by Geographic Area in 2024
11.1.8 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
11.1.9 Gilead Sciences Recent Developments
11.2 ViiV Healthcare
11.2.1 ViiV Healthcare Corporation Information
11.2.2 ViiV Healthcare Business Overview
11.2.3 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.2.4 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Sales by Product in 2024
11.2.6 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Sales by Application in 2024
11.2.7 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Sales by Geographic Area in 2024
11.2.8 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
11.2.9 ViiV Healthcare Recent Developments
11.3 Teva
11.3.1 Teva Corporation Information
11.3.2 Teva Business Overview
11.3.3 Teva Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.3.4 Teva Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Teva Pre-Exposure Prophylaxis (PrEP) Sales by Product in 2024
11.3.6 Teva Pre-Exposure Prophylaxis (PrEP) Sales by Application in 2024
11.3.7 Teva Pre-Exposure Prophylaxis (PrEP) Sales by Geographic Area in 2024
11.3.8 Teva Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
11.3.9 Teva Recent Developments
11.4 Amneal Pharmaceuticals
11.4.1 Amneal Pharmaceuticals Corporation Information
11.4.2 Amneal Pharmaceuticals Business Overview
11.4.3 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.4.4 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Sales by Product in 2024
11.4.6 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Sales by Application in 2024
11.4.7 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Sales by Geographic Area in 2024
11.4.8 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
11.4.9 Amneal Pharmaceuticals Recent Developments
11.5 Aurobindo Pharma
11.5.1 Aurobindo Pharma Corporation Information
11.5.2 Aurobindo Pharma Business Overview
11.5.3 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.5.4 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Sales by Product in 2024
11.5.6 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Sales by Application in 2024
11.5.7 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Sales by Geographic Area in 2024
11.5.8 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
11.5.9 Aurobindo Pharma Recent Developments
11.6 Mylan
11.6.1 Mylan Corporation Information
11.6.2 Mylan Business Overview
11.6.3 Mylan Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.6.4 Mylan Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Mylan Recent Developments
11.7 Zydus
11.7.1 Zydus Corporation Information
11.7.2 Zydus Business Overview
11.7.3 Zydus Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.7.4 Zydus Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Zydus Recent Developments
11.8 Qilu Pharmaceutical
11.8.1 Qilu Pharmaceutical Corporation Information
11.8.2 Qilu Pharmaceutical Business Overview
11.8.3 Qilu Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.8.4 Qilu Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Qilu Pharmaceutical Recent Developments
11.9 Anhui Baker Biopharmaceutical
11.9.1 Anhui Baker Biopharmaceutical Corporation Information
11.9.2 Anhui Baker Biopharmaceutical Business Overview
11.9.3 Anhui Baker Biopharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.9.4 Anhui Baker Biopharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Anhui Baker Biopharmaceutical Recent Developments
11.10 Chengdu Brilliant Pharmaceutical
11.10.1 Chengdu Brilliant Pharmaceutical Corporation Information
11.10.2 Chengdu Brilliant Pharmaceutical Business Overview
11.10.3 Chengdu Brilliant Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.10.4 Chengdu Brilliant Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Chengdu Brilliant Pharmaceutical Recent Developments
11.11 North China Pharmaceutical
11.11.1 North China Pharmaceutical Corporation Information
11.11.2 North China Pharmaceutical Business Overview
11.11.3 North China Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.11.4 North China Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 North China Pharmaceutical Recent Developments
11.12 Chia Tai Tianqing Pharmaceutical
11.12.1 Chia Tai Tianqing Pharmaceutical Corporation Information
11.12.2 Chia Tai Tianqing Pharmaceutical Business Overview
11.12.3 Chia Tai Tianqing Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Models, Descriptions and Specifications
11.12.4 Chia Tai Tianqing Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Pre-Exposure Prophylaxis (PrEP) Industry Chain
12.2 Pre-Exposure Prophylaxis (PrEP) Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Pre-Exposure Prophylaxis (PrEP) Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Pre-Exposure Prophylaxis (PrEP) Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Pre-Exposure Prophylaxis (PrEP) Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Pre-Exposure Prophylaxis (PrEP) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Pre-Exposure Prophylaxis (PrEP) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Pre-Exposure Prophylaxis (PrEP) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Pre-Exposure Prophylaxis (PrEP) Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Pre-Exposure Prophylaxis (PrEP) Sales by Region (2020-2025) & (K Units)
Table 8. Global Pre-Exposure Prophylaxis (PrEP) Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Pre-Exposure Prophylaxis (PrEP) Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Pre-Exposure Prophylaxis (PrEP) Sales Share by Manufacturers (2020-2025)
Table 12. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Pre-Exposure Prophylaxis (PrEP) by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pre-Exposure Prophylaxis (PrEP) as of 2024)
Table 16. Global Pre-Exposure Prophylaxis (PrEP) Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Pre-Exposure Prophylaxis (PrEP) Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Pre-Exposure Prophylaxis (PrEP) Manufacturing Base and Headquarters
Table 19. Global Pre-Exposure Prophylaxis (PrEP) Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Pre-Exposure Prophylaxis (PrEP) Sales by Type (2020-2025) & (K Units)
Table 23. Global Pre-Exposure Prophylaxis (PrEP) Sales by Type (2026-2031) & (K Units)
Table 24. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Pre-Exposure Prophylaxis (PrEP) ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Pre-Exposure Prophylaxis (PrEP) Sales by Application (2020-2025) & (K Units)
Table 29. Global Pre-Exposure Prophylaxis (PrEP) Sales by Application (2026-2031) & (K Units)
Table 30. Pre-Exposure Prophylaxis (PrEP) High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Pre-Exposure Prophylaxis (PrEP) ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Pre-Exposure Prophylaxis (PrEP) Growth Accelerators and Market Barriers
Table 37. North America Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Pre-Exposure Prophylaxis (PrEP) Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Pre-Exposure Prophylaxis (PrEP) Growth Accelerators and Market Barriers
Table 40. Europe Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Pre-Exposure Prophylaxis (PrEP) Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Growth Accelerators and Market Barriers
Table 45. Southeast Asia Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Pre-Exposure Prophylaxis (PrEP) Investment Opportunities and Key Challenges
Table 47. Central and South America Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Gilead Sciences Corporation Information
Table 51. Gilead Sciences Description and Major Businesses
Table 52. Gilead Sciences Product Models, Descriptions and Specifications
Table 53. Gilead Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Gilead Sciences Sales Value Proportion by Product in 2024
Table 55. Gilead Sciences Sales Value Proportion by Application in 2024
Table 56. Gilead Sciences Sales Value Proportion by Geographic Area in 2024
Table 57. Gilead Sciences Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
Table 58. Gilead Sciences Recent Developments
Table 59. ViiV Healthcare Corporation Information
Table 60. ViiV Healthcare Description and Major Businesses
Table 61. ViiV Healthcare Product Models, Descriptions and Specifications
Table 62. ViiV Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. ViiV Healthcare Sales Value Proportion by Product in 2024
Table 64. ViiV Healthcare Sales Value Proportion by Application in 2024
Table 65. ViiV Healthcare Sales Value Proportion by Geographic Area in 2024
Table 66. ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
Table 67. ViiV Healthcare Recent Developments
Table 68. Teva Corporation Information
Table 69. Teva Description and Major Businesses
Table 70. Teva Product Models, Descriptions and Specifications
Table 71. Teva Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Teva Sales Value Proportion by Product in 2024
Table 73. Teva Sales Value Proportion by Application in 2024
Table 74. Teva Sales Value Proportion by Geographic Area in 2024
Table 75. Teva Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
Table 76. Teva Recent Developments
Table 77. Amneal Pharmaceuticals Corporation Information
Table 78. Amneal Pharmaceuticals Description and Major Businesses
Table 79. Amneal Pharmaceuticals Product Models, Descriptions and Specifications
Table 80. Amneal Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Amneal Pharmaceuticals Sales Value Proportion by Product in 2024
Table 82. Amneal Pharmaceuticals Sales Value Proportion by Application in 2024
Table 83. Amneal Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 84. Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
Table 85. Amneal Pharmaceuticals Recent Developments
Table 86. Aurobindo Pharma Corporation Information
Table 87. Aurobindo Pharma Description and Major Businesses
Table 88. Aurobindo Pharma Product Models, Descriptions and Specifications
Table 89. Aurobindo Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Aurobindo Pharma Sales Value Proportion by Product in 2024
Table 91. Aurobindo Pharma Sales Value Proportion by Application in 2024
Table 92. Aurobindo Pharma Sales Value Proportion by Geographic Area in 2024
Table 93. Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
Table 94. Aurobindo Pharma Recent Developments
Table 95. Mylan Corporation Information
Table 96. Mylan Description and Major Businesses
Table 97. Mylan Product Models, Descriptions and Specifications
Table 98. Mylan Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Mylan Recent Developments
Table 100. Zydus Corporation Information
Table 101. Zydus Description and Major Businesses
Table 102. Zydus Product Models, Descriptions and Specifications
Table 103. Zydus Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Zydus Recent Developments
Table 105. Qilu Pharmaceutical Corporation Information
Table 106. Qilu Pharmaceutical Description and Major Businesses
Table 107. Qilu Pharmaceutical Product Models, Descriptions and Specifications
Table 108. Qilu Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Qilu Pharmaceutical Recent Developments
Table 110. Anhui Baker Biopharmaceutical Corporation Information
Table 111. Anhui Baker Biopharmaceutical Description and Major Businesses
Table 112. Anhui Baker Biopharmaceutical Product Models, Descriptions and Specifications
Table 113. Anhui Baker Biopharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Anhui Baker Biopharmaceutical Recent Developments
Table 115. Chengdu Brilliant Pharmaceutical Corporation Information
Table 116. Chengdu Brilliant Pharmaceutical Description and Major Businesses
Table 117. Chengdu Brilliant Pharmaceutical Product Models, Descriptions and Specifications
Table 118. Chengdu Brilliant Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Chengdu Brilliant Pharmaceutical Recent Developments
Table 120. North China Pharmaceutical Corporation Information
Table 121. North China Pharmaceutical Description and Major Businesses
Table 122. North China Pharmaceutical Product Models, Descriptions and Specifications
Table 123. North China Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. North China Pharmaceutical Recent Developments
Table 125. Chia Tai Tianqing Pharmaceutical Corporation Information
Table 126. Chia Tai Tianqing Pharmaceutical Description and Major Businesses
Table 127. Chia Tai Tianqing Pharmaceutical Product Models, Descriptions and Specifications
Table 128. Chia Tai Tianqing Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Chia Tai Tianqing Pharmaceutical Recent Developments
Table 130. Key Raw Materials Distribution
Table 131. Raw Materials Key Suppliers
Table 132. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 133. Milestones in Production Technology Evolution
Table 134. Distributors List
Table 135. Market Trends and Market Evolution
Table 136. Market Drivers and Opportunities
Table 137. Market Challenges, Risks, and Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Pre-Exposure Prophylaxis (PrEP) Product Picture
Figure 2. Global Pre-Exposure Prophylaxis (PrEP) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Oral PrEP Product Picture
Figure 4. Injectable PrEP Product Picture
Figure 5. Global Pre-Exposure Prophylaxis (PrEP) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital and Clinic
Figure 7. Pharmacy
Figure 8. Other
Figure 9. Pre-Exposure Prophylaxis (PrEP) Report Years Considered
Figure 10. Global Pre-Exposure Prophylaxis (PrEP) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 12. Global Pre-Exposure Prophylaxis (PrEP) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Region (2020-2031)
Figure 14. Global Pre-Exposure Prophylaxis (PrEP) Sales (2020-2031) & (K Units)
Figure 15. Global Pre-Exposure Prophylaxis (PrEP) Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Pre-Exposure Prophylaxis (PrEP) Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Volume Market Share in 2024
Figure 18. Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Oral PrEP Revenue Market Share by Manufacturer in 2024
Figure 21. Injectable PrEP Revenue Market Share by Manufacturer in 2024
Figure 22. Global Pre-Exposure Prophylaxis (PrEP) Sales Market Share by Type (2020-2031)
Figure 23. Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Type (2020-2031)
Figure 24. Global Pre-Exposure Prophylaxis (PrEP) Sales Market Share by Application (2020-2031)
Figure 25. Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Application (2020-2031)
Figure 26. North America Pre-Exposure Prophylaxis (PrEP) Sales YoY (2020-2031) & (K Units)
Figure 27. North America Pre-Exposure Prophylaxis (PrEP) Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) in 2024
Figure 29. North America Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Pre-Exposure Prophylaxis (PrEP) Sales YoY (2020-2031) & (K Units)
Figure 37. Europe Pre-Exposure Prophylaxis (PrEP) Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) in 2024
Figure 39. Europe Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 44. France Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 59. India Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Pre-Exposure Prophylaxis (PrEP) Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America Pre-Exposure Prophylaxis (PrEP) Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Pre-Exposure Prophylaxis (PrEP) Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 80. Pre-Exposure Prophylaxis (PrEP) Industry Chain Mapping
Figure 81. Regional Pre-Exposure Prophylaxis (PrEP) Manufacturing Base Distribution (%)
Figure 82. Global Pre-Exposure Prophylaxis (PrEP) Production Market Share by Region (2020-2031)
Figure 83. Pre-Exposure Prophylaxis (PrEP) Production Process
Figure 84. Regional Pre-Exposure Prophylaxis (PrEP) Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Table 1. Global Pre-Exposure Prophylaxis (PrEP) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Pre-Exposure Prophylaxis (PrEP) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Pre-Exposure Prophylaxis (PrEP) Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Pre-Exposure Prophylaxis (PrEP) Sales by Region (2020-2025) & (K Units)
Table 8. Global Pre-Exposure Prophylaxis (PrEP) Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Pre-Exposure Prophylaxis (PrEP) Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Pre-Exposure Prophylaxis (PrEP) Sales Share by Manufacturers (2020-2025)
Table 12. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Pre-Exposure Prophylaxis (PrEP) by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pre-Exposure Prophylaxis (PrEP) as of 2024)
Table 16. Global Pre-Exposure Prophylaxis (PrEP) Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Pre-Exposure Prophylaxis (PrEP) Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Pre-Exposure Prophylaxis (PrEP) Manufacturing Base and Headquarters
Table 19. Global Pre-Exposure Prophylaxis (PrEP) Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Pre-Exposure Prophylaxis (PrEP) Sales by Type (2020-2025) & (K Units)
Table 23. Global Pre-Exposure Prophylaxis (PrEP) Sales by Type (2026-2031) & (K Units)
Table 24. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Pre-Exposure Prophylaxis (PrEP) ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Pre-Exposure Prophylaxis (PrEP) Sales by Application (2020-2025) & (K Units)
Table 29. Global Pre-Exposure Prophylaxis (PrEP) Sales by Application (2026-2031) & (K Units)
Table 30. Pre-Exposure Prophylaxis (PrEP) High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Pre-Exposure Prophylaxis (PrEP) Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Pre-Exposure Prophylaxis (PrEP) ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Pre-Exposure Prophylaxis (PrEP) Growth Accelerators and Market Barriers
Table 37. North America Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Pre-Exposure Prophylaxis (PrEP) Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Pre-Exposure Prophylaxis (PrEP) Growth Accelerators and Market Barriers
Table 40. Europe Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Pre-Exposure Prophylaxis (PrEP) Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Growth Accelerators and Market Barriers
Table 45. Southeast Asia Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Pre-Exposure Prophylaxis (PrEP) Investment Opportunities and Key Challenges
Table 47. Central and South America Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Gilead Sciences Corporation Information
Table 51. Gilead Sciences Description and Major Businesses
Table 52. Gilead Sciences Product Models, Descriptions and Specifications
Table 53. Gilead Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Gilead Sciences Sales Value Proportion by Product in 2024
Table 55. Gilead Sciences Sales Value Proportion by Application in 2024
Table 56. Gilead Sciences Sales Value Proportion by Geographic Area in 2024
Table 57. Gilead Sciences Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
Table 58. Gilead Sciences Recent Developments
Table 59. ViiV Healthcare Corporation Information
Table 60. ViiV Healthcare Description and Major Businesses
Table 61. ViiV Healthcare Product Models, Descriptions and Specifications
Table 62. ViiV Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. ViiV Healthcare Sales Value Proportion by Product in 2024
Table 64. ViiV Healthcare Sales Value Proportion by Application in 2024
Table 65. ViiV Healthcare Sales Value Proportion by Geographic Area in 2024
Table 66. ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
Table 67. ViiV Healthcare Recent Developments
Table 68. Teva Corporation Information
Table 69. Teva Description and Major Businesses
Table 70. Teva Product Models, Descriptions and Specifications
Table 71. Teva Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Teva Sales Value Proportion by Product in 2024
Table 73. Teva Sales Value Proportion by Application in 2024
Table 74. Teva Sales Value Proportion by Geographic Area in 2024
Table 75. Teva Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
Table 76. Teva Recent Developments
Table 77. Amneal Pharmaceuticals Corporation Information
Table 78. Amneal Pharmaceuticals Description and Major Businesses
Table 79. Amneal Pharmaceuticals Product Models, Descriptions and Specifications
Table 80. Amneal Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Amneal Pharmaceuticals Sales Value Proportion by Product in 2024
Table 82. Amneal Pharmaceuticals Sales Value Proportion by Application in 2024
Table 83. Amneal Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 84. Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
Table 85. Amneal Pharmaceuticals Recent Developments
Table 86. Aurobindo Pharma Corporation Information
Table 87. Aurobindo Pharma Description and Major Businesses
Table 88. Aurobindo Pharma Product Models, Descriptions and Specifications
Table 89. Aurobindo Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Aurobindo Pharma Sales Value Proportion by Product in 2024
Table 91. Aurobindo Pharma Sales Value Proportion by Application in 2024
Table 92. Aurobindo Pharma Sales Value Proportion by Geographic Area in 2024
Table 93. Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) SWOT Analysis
Table 94. Aurobindo Pharma Recent Developments
Table 95. Mylan Corporation Information
Table 96. Mylan Description and Major Businesses
Table 97. Mylan Product Models, Descriptions and Specifications
Table 98. Mylan Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Mylan Recent Developments
Table 100. Zydus Corporation Information
Table 101. Zydus Description and Major Businesses
Table 102. Zydus Product Models, Descriptions and Specifications
Table 103. Zydus Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Zydus Recent Developments
Table 105. Qilu Pharmaceutical Corporation Information
Table 106. Qilu Pharmaceutical Description and Major Businesses
Table 107. Qilu Pharmaceutical Product Models, Descriptions and Specifications
Table 108. Qilu Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Qilu Pharmaceutical Recent Developments
Table 110. Anhui Baker Biopharmaceutical Corporation Information
Table 111. Anhui Baker Biopharmaceutical Description and Major Businesses
Table 112. Anhui Baker Biopharmaceutical Product Models, Descriptions and Specifications
Table 113. Anhui Baker Biopharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Anhui Baker Biopharmaceutical Recent Developments
Table 115. Chengdu Brilliant Pharmaceutical Corporation Information
Table 116. Chengdu Brilliant Pharmaceutical Description and Major Businesses
Table 117. Chengdu Brilliant Pharmaceutical Product Models, Descriptions and Specifications
Table 118. Chengdu Brilliant Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Chengdu Brilliant Pharmaceutical Recent Developments
Table 120. North China Pharmaceutical Corporation Information
Table 121. North China Pharmaceutical Description and Major Businesses
Table 122. North China Pharmaceutical Product Models, Descriptions and Specifications
Table 123. North China Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. North China Pharmaceutical Recent Developments
Table 125. Chia Tai Tianqing Pharmaceutical Corporation Information
Table 126. Chia Tai Tianqing Pharmaceutical Description and Major Businesses
Table 127. Chia Tai Tianqing Pharmaceutical Product Models, Descriptions and Specifications
Table 128. Chia Tai Tianqing Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Chia Tai Tianqing Pharmaceutical Recent Developments
Table 130. Key Raw Materials Distribution
Table 131. Raw Materials Key Suppliers
Table 132. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 133. Milestones in Production Technology Evolution
Table 134. Distributors List
Table 135. Market Trends and Market Evolution
Table 136. Market Drivers and Opportunities
Table 137. Market Challenges, Risks, and Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Pre-Exposure Prophylaxis (PrEP) Product Picture
Figure 2. Global Pre-Exposure Prophylaxis (PrEP) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Oral PrEP Product Picture
Figure 4. Injectable PrEP Product Picture
Figure 5. Global Pre-Exposure Prophylaxis (PrEP) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital and Clinic
Figure 7. Pharmacy
Figure 8. Other
Figure 9. Pre-Exposure Prophylaxis (PrEP) Report Years Considered
Figure 10. Global Pre-Exposure Prophylaxis (PrEP) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 12. Global Pre-Exposure Prophylaxis (PrEP) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Region (2020-2031)
Figure 14. Global Pre-Exposure Prophylaxis (PrEP) Sales (2020-2031) & (K Units)
Figure 15. Global Pre-Exposure Prophylaxis (PrEP) Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Pre-Exposure Prophylaxis (PrEP) Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Volume Market Share in 2024
Figure 18. Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Oral PrEP Revenue Market Share by Manufacturer in 2024
Figure 21. Injectable PrEP Revenue Market Share by Manufacturer in 2024
Figure 22. Global Pre-Exposure Prophylaxis (PrEP) Sales Market Share by Type (2020-2031)
Figure 23. Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Type (2020-2031)
Figure 24. Global Pre-Exposure Prophylaxis (PrEP) Sales Market Share by Application (2020-2031)
Figure 25. Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Application (2020-2031)
Figure 26. North America Pre-Exposure Prophylaxis (PrEP) Sales YoY (2020-2031) & (K Units)
Figure 27. North America Pre-Exposure Prophylaxis (PrEP) Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) in 2024
Figure 29. North America Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Pre-Exposure Prophylaxis (PrEP) Sales YoY (2020-2031) & (K Units)
Figure 37. Europe Pre-Exposure Prophylaxis (PrEP) Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) in 2024
Figure 39. Europe Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 44. France Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 59. India Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Pre-Exposure Prophylaxis (PrEP) Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America Pre-Exposure Prophylaxis (PrEP) Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Pre-Exposure Prophylaxis (PrEP) Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Pre-Exposure Prophylaxis (PrEP) Revenue (2020-2025) & (US$ Million)
Figure 80. Pre-Exposure Prophylaxis (PrEP) Industry Chain Mapping
Figure 81. Regional Pre-Exposure Prophylaxis (PrEP) Manufacturing Base Distribution (%)
Figure 82. Global Pre-Exposure Prophylaxis (PrEP) Production Market Share by Region (2020-2031)
Figure 83. Pre-Exposure Prophylaxis (PrEP) Production Process
Figure 84. Regional Pre-Exposure Prophylaxis (PrEP) Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232